Novartis has announced that the European Commission has expanded the approval of its multiple sclerosis drug, Gilenya (fingolimod), to include the treatment of children and adolescents aged 10 to 17 years with relapsing-remitting multiple sclerosis. This approval marks Gilenya as the first oral disease-modifying therapy authorized for this younger demographic in Europe. Pioneering oral therapy […]
Sanofi and Principia Biopharma have announced a significant partnership to develop and commercialize PRN2246, a promising oral drug candidate for multiple sclerosis (MS) and other central nervous system (CNS) diseases. The deal, which could be worth up to $805 million, positions PRN2246, a Bruton’s tyrosine kinase (BTK) inhibitor, at the forefront of MS treatment development. […]
Roche Group’s subsidiary Genentech has secured the US FDA approval for its multiple sclerosis drug, Ocrevus (ocrelizumab) for treating both relapsing and primary progressive variants of the chronic disease through intravenous infusion.
In a landmark decision, the US Food and Drug Administration (FDA) has granted approval to Genentech, a subsidiary of the Roche Group, for its multiple sclerosis (MS) drug, Ocrevus (ocrelizumab). This approval marks Ocrevus as the first and only therapy available for both relapsing and primary progressive forms of multiple sclerosis, addressing a significant unmet […]